These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
341 related articles for article (PubMed ID: 24286577)
21. The neurohumoral axis in congestive heart failure. Francis GS; Goldsmith SR; Levine TB; Olivari MT; Cohn JN Ann Intern Med; 1984 Sep; 101(3):370-7. PubMed ID: 6147109 [TBL] [Abstract][Full Text] [Related]
22. New concepts in post-infarction ventricular remodeling. Udelson JE; Patten RD; Konstam MA Rev Cardiovasc Med; 2003; 4 Suppl 3():S3-12. PubMed ID: 14564229 [TBL] [Abstract][Full Text] [Related]
23. Drug therapy of chronic heart failure in the elderly: the current state of clinical-trial evidence. Dulin BR; Krum H Curr Opin Cardiol; 2006 Jul; 21(4):393-9. PubMed ID: 16755210 [TBL] [Abstract][Full Text] [Related]
24. Combination Therapy of Renin Angiotensin System Inhibitors and β-Blockers in Patients with Heart Failure. Nochioka K; Sakata Y; Shimokawa H Adv Exp Med Biol; 2018; 1067():17-30. PubMed ID: 29542073 [TBL] [Abstract][Full Text] [Related]
25. Adrenergic nervous system in heart failure: pathophysiology and therapy. Lymperopoulos A; Rengo G; Koch WJ Circ Res; 2013 Aug; 113(6):739-53. PubMed ID: 23989716 [TBL] [Abstract][Full Text] [Related]
26. Time and technology will tell: the pathophysiologic basis of neurohormonal modulation in heart failure. Reed BN; Street SE; Jensen BC Heart Fail Clin; 2014 Oct; 10(4):543-57. PubMed ID: 25217430 [TBL] [Abstract][Full Text] [Related]
28. Overview of recent clinical trials in heart failure: what is the current standard of care? Murray DR; Dugan J Cardiol Rev; 2000; 8(6):340-7. PubMed ID: 11208254 [TBL] [Abstract][Full Text] [Related]
29. [Adrenergic activation in heart failure: blockade or rebalance?]. Emdin M; Vergaro G; Giannoni A; Passino C G Ital Cardiol (Rome); 2010 Mar; 11(3):229-32. PubMed ID: 20550063 [No Abstract] [Full Text] [Related]
30. Multiple renin-angiotensin-aldosterone-blocking agents in heart failure: how much is too much? Pitt B Curr Heart Fail Rep; 2009 Jun; 6(2):112-6. PubMed ID: 19486595 [TBL] [Abstract][Full Text] [Related]
31. Cardiac afferents and neurohormonal activation in congestive heart failure. Davila DF; Donis JH; Bellabarba G; Torres A; Casado J; Mazzei de Davila C Med Hypotheses; 2000 Feb; 54(2):242-53. PubMed ID: 10790760 [TBL] [Abstract][Full Text] [Related]
32. Mineralocorticoid receptor antagonism: therapeutic potential in acute heart failure syndromes. Albaghdadi M; Gheorghiade M; Pitt B Eur Heart J; 2011 Nov; 32(21):2626-33. PubMed ID: 21672933 [TBL] [Abstract][Full Text] [Related]
33. Update in the approach to and management of heart failure. Gelow JM; Fang JC South Med J; 2006 Dec; 99(12):1346-55; quiz 1356-7, 1384. PubMed ID: 17233191 [TBL] [Abstract][Full Text] [Related]
39. Pathophysiology of sodium and water retention in heart failure. Cadnapaphornchai MA; Gurevich AK; Weinberger HD; Schrier RW Cardiology; 2001; 96(3-4):122-31. PubMed ID: 11805379 [TBL] [Abstract][Full Text] [Related]
40. Congestive heart failure: what should be the initial therapy and why? Chatterjee K Am J Cardiovasc Drugs; 2002; 2(1):1-6. PubMed ID: 14727993 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]